Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics IL-5 Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    IL-5 Inhibitors Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, renewal, and quantity-limit approval for Fasenra (benralizumab) and Nucala (mepolizumab) for covered eosinophilic and related inflammatory conditions. It applies to Boeing commercial members and requires clinical documentation, condition-specific maintenance therapy, specialist involvement, and review of concomitant immunomodulator use.

    Policy Summary
    PayerPrime Therapeutics
    PolicyIL-5 Inhibitors Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date11-01-2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Fasenra or Nucala with required clinical documentation and specialist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Target drugs
    12 monthsApproval length
    5Covered indications
    90 daysContinuation window

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 weeksCRSwNP symptom duration

    Coverage Criteria

    Continuation and Renewal Therapy

    The target agent will be approved for renewal when ALL of the following are met:

    ALL of the following

    • The patient was previously approved for the requested agent through the plan's prior authorization process; patients not previously approved require initial evaluation review.
    • The patient has had clinical benefit with the requested agent.
    • If the patient has severe eosinophilic asthma, the patient is currently treated within the past 90 days and is compliant with asthma control therapy, such as ICS, ICS/LABA, LTRA, LAMA, or theophylline; chart notes are required.
    • If the patient has COPD, the patient is currently treated within the past 90 days and is compliant with COPD inhaled maintenance therapy, including ICS/LAMA/LABA triple therapy or LAMA/LABA dual therapy; chart notes are required.
    • If the patient has CRSwNP, the patient will continue standard nasal polyp maintenance therapy, such as nasal saline irrigation or intranasal corticosteroids, in combination with the requested agent.
    • The prescriber is a specialist in the area of the patient's diagnosis or has consulted with an appropriate specialist.
    • ONE of the following concomitant immunomodulatory therapy pathways

      • The patient will not use the requested agent in combination with another immunomodulatory agent, such as a TNF inhibitor, JAK inhibitor, or IL-4 inhibitor.
      • ALL of the following

        • The patient will use the requested agent with another immunomodulatory agent.
        • The prescribing information for the requested agent does not limit use with another immunomodulatory agent.
        • Support for combination therapy is provided, such as clinical trials, phase III studies, or guidelines.
    • The patient does not have any FDA-labeled contraindications to the requested agent.

    Severe Eosinophilic Asthma

    For severe eosinophilic asthma, ALL applicable criteria must be met:

    ALL of the following

    • The patient has severe eosinophilic asthma confirmed by the required eosinophil or FeNO findings while on high-dose inhaled corticosteroid or daily oral corticosteroid therapy.
    • ANY of the following

      • At least 2 severe asthma exacerbations requiring a systemic corticosteroid burst within the past 12 months.
      • At least 1 serious asthma exacerbation requiring hospitalization, mechanical ventilation, or emergency-room or urgent-care treatment within the past 12 months.
      • Controlled asthma worsens when inhaled and/or systemic corticosteroid doses are tapered.

    Eosinophilic COPD

    For eosinophilic COPD, ALL of the following must be met:

    ALL of the following

    • The patient has COPD confirmed by post-bronchodilator FEV1/FVC less than 0.7.
    • The requested agent is FDA labeled or supported in compendia for COPD.
    • Baseline blood eosinophil count is at least 300 cells/microliter.
    • ANY of the following

      • At least 2 moderate COPD exacerbations or at least 1 severe COPD exacerbation occurred within the past 12 months while on COPD inhaled maintenance therapy.
      • A biologic immunomodulator FDA labeled or supported in compendia for COPD was used within the past 12 months, excluding sample use.

    Hypereosinophilic Syndrome (HES)

    For HES, ALL of the following must be met:

    ALL of the following

    • If the requested agent is Nucala, the patient has had HES for at least 6 months.
    • Baseline blood eosinophil count is at least 1,000 cells/microliter.
    • Evaluation for hypereosinophilia-related organ involvement has been completed.
    • No identifiable non-hematologic secondary/reactive cause of HES is present.
    • The patient does not have FIP1L1-PDGFRA-positive disease.
    • ANY of the following

    Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

    For CRSwNP, ALL of the following must be met:

    ALL of the following

    • The requested agent is FDA labeled or supported in compendia for CRSwNP.
    • At least TWO symptoms

      • Nasal discharge.
      • Nasal obstruction or congestion.
      • Loss or decreased sense of smell.
      • Facial pressure or pain.

    Prior Authorization Clinical Approval

    Prior authorization clinical approval requires the following clinical requirements:

    ALL of the following

    • The requested agent meets the applicable initial-therapy or continuation/renewal criteria for a covered indication.
    • All indication-specific clinical, laboratory, treatment-history, concomitant-therapy, specialist, and contraindication requirements are documented, as applicable.
    • The requested use is FDA labeled or supported in compendia. Allowed compendia include AHFS, DrugDex level 1, 2a, or 2b evidence, and NCCN level 1, 2a, or 2b recommended use.
    • The approval duration is 12 months.
    • If a quantity limit applies, the quantity-limit criteria must also be met.

    The patient must not have severe disease with organ- or life-threatening manifestations, including alveolar hemorrhage, glomerulonephritis, central nervous system vasculitis, mononeuritis multiplex, cardiac involvement, mesenteric ischemia, or limb/digit ischemia. Required chart notes and laboratory results must support the baseline eosinophil criterion and the applicable oral corticosteroid pathway.

    The patient must not have an identifiable non-hematologic secondary/reactive cause of HES, including infection, allergy or atopy, autoimmune disease, drug reaction, metabolic condition, or solid tumor/lymphoma. The patient must not have FIP1L1-PDGFRA-positive disease. If the requested agent is Nucala, HES must have been diagnosed for at least 6 months; baseline eosinophils must be at least 1,000 cells/microliter, and evaluation for hypereosinophilia-related organ involvement must be documented.

    Agents listed as contraindicated as concomitant therapy include Abrilada (adalimumab-afzb), Actemra (tocilizumab), Adalimumab, Adbry (tralokinumab-ldrm), Amjevita (adalimumab-atto), Anzupgo (delgocitinib), Arcalyst (rilonacept), Avsola (infliximab-axxq), Avtozma (tocilizumab-anoh), Benlysta (belimumab), Bimzelx (bimekizumab-bkzx), Cibinqo (abrocitinib), Cimzia (certolizumab), Cinqair (reslizumab), Cosentyx (secukinumab), Cyltezo (adalimumab-adbm), Dupixent (dupilumab), Ebglyss (lebrikizumab-lbkz), Enbrel (etanercept), Entyvio (vedolizumab), Exdensur (depemokimab-ulaa), Fasenra (benralizumab), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Humira (adalimumab), Hyrimoz (adalimumab-adaz), Icotyde (icotrokinra), Idacio (adalimumab-aacf), Ilaris (canakinumab), Ilumya (tildrakizumab-asmn), Imuldosa (ustekinumab-srlf), Inflectra (infliximab-dyyb), Infliximab, Kevzara (sarilumab), Kineret (anakinra), Leqselvi (deuruxolitinib), Litfulo (ritlecitinib), Nemluvio (nemolizumab-ilto), Nucala (mepolizumab), Olumiant (baricitinib), Omlyclo (omalizumab-igec), Omvoh (mirikizumab-mrkz), Opzelura (ruxolitinib), Orencia (abatacept), Otezla and Otezla XR (apremilast), Otulfi (ustekinumab-aauz), Pyzchiva (ustekinumab-ttwe), Remicade (infliximab), Renflexis (infliximab-abda), Rhapsido (remibrutinib), Riabni (rituximab-arrx), Rinvoq (upadacitinib), Rituxan and Rituxan Hycela (rituximab or rituximab/hyaluronidase), Ruxience (rituximab-pvvr), Saphnelo (anifrolumab-fnia), Selarsdi (ustekinumab-aekn), Siliq (brodalumab), Simlandi (adalimumab-ryvk), Simponi and Simponi ARIA (golimumab), Skyrizi (risankizumab-rzaa), Sotyktu (deucravacitinib), Spevigo (spesolimab-sbzo), Starjemza (ustekinumab-hmny), Stelara (ustekinumab), Steqeyma (ustekinumab-stba), Taltz (ixekizumab), Tezspire (tezepelumab-ekko), Tofacitinib, Tofidence (tocilizumab-bavi), Tremfya (guselkumab), Truxima (rituximab-abbs), Tyenne (tocilizumab-aazg), Tyruko (natalizumab-sztn), Tysabri (natalizumab), Ustekinumab, Velsipity (etrasimod), Wezlana (ustekinumab-auub), Xeljanz and Xeljanz XR (tofacitinib), Xolair (omalizumab), Yesintek (ustekinumab-kfce), Yuflyma (adalimumab-aaty), Yusimry (adalimumab-aqvh), Zeposia (ozanimod), and Zymfentra (infliximab-dyyb). For Boeing groups, healthcare-professional-administered Nucala (GPI 44604055002120) and Fasenra (GPI 4460402000E520) may be covered under a pharmacy-benefit route-of-administration exception; other groups may exclude those products from the pharmacy benefit.

    Coding and Clinical Thresholds

    Healthcare professional administered product GPIsGPI
    44604055002120GPI for healthcare professional administered Nucala
    4460402000E520GPI for healthcare professional administered Fasenra
    Severe asthma baseline eosinophils
    ThresholdBaseline blood eosinophil count of >= 150 cells/microliter
    TimingMeasured prior to therapy with the requested agent
    Clinical contextSupports severe eosinophilic asthma diagnosis while receiving high-dose inhaled corticosteroid or daily oral corticosteroid therapy
    Severe asthma FeNO
    ThresholdFeNO of >= 20 parts per billion
    TimingMeasured while confirming the diagnosis before therapy with the requested agent
    Clinical context

    Provider Actions and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for all target IL-5 inhibitor agents. Submit an initial or renewal request with documentation supporting the applicable clinical pathway. Approved initial and renewal authorizations are limited to 12 months.

    • Continuation requests require evidence that the patient has been treated with the requested agent within the past 90 days, excluding samples, and is at risk if therapy is changed.
    • Initial requests must establish an approved diagnosis, treatment history, required maintenance therapy, specialist involvement, and all applicable safety criteria.
    Prior Authorization

    Quantity-Limit Authorization

    Requests exceeding the program quantity limit require a quantity-limit exception review. Quantity-limit approvals are limited to 12 months.

    • Quantities at or below the program limit may be approved when otherwise eligible.
    • For quantities above the limit, submit the required FDA-label and clinical-support documentation.

    Policy Background

    IL-5 inhibitors are biologic immunomodulators used for selected eosinophilic airway and systemic inflammatory diseases. This policy addresses severe eosinophilic asthma, eosinophilic chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps when the requested agent is FDA-labeled or compendia-supported for the indication and route. Approval generally requires objective disease confirmation, inadequate control or relevant prior therapy, continuation of standard maintenance treatment, and specialist oversight.

    Clinical Definitions

    Severe eosinophilic asthma
    DefinitionAsthma requiring high-dose inhaled corticosteroid or daily oral corticosteroid therapy
    Objective supportSupported by baseline eosinophils >= 150 cells/microliter, FeNO >= 20 parts per billion, or baseline FEV1 < 80% of predicted
    Disease-control supportMay include qualifying exacerbations, worsening when corticosteroids are tapered, or recent biologic immunomodulator use
    Eosinophilic COPD
    DefinitionCOPD confirmed by post-bronchodilator spirometry with an FEV1/FVC ratio < 0.7
    Eosinophilic phenotypeBaseline blood eosinophils >= 300 cells/microliter

    Initial Authorization

    Initial Authorization

    Initial target-agent approval requires ALL general conditions and ONE applicable indication pathway.

    Initial authorization

    • Continuation or covered indication pathway: The requested agent is eligible for continuation because the patient was treated with it within the past 90 days, excluding samples, and is at risk if therapy is changed; OR the patient meets one applicable pathway for severe eosinophilic asthma, COPD, EGPA, HES, CRSwNP, or another FDA-labeled or compendia-supported indication.

    Clinical Authorization Requirements

    Prior authorization clinical criteria for approval.

    Clinical authorization requirements

    • Specialist requirement: The prescriber is a specialist in the area of the patient's diagnosis OR has consulted with an appropriate specialist.

    Continuation and Renewal

    Continuation and Renewal

    Renewal target agents will be approved when ALL of the following are met.

    Continuation and renewal: The patient was previously approved for the requested agent through the plan's prior authorization process; the patient has had clinical benefit with the requested agent; required disease-specific maintenance therapy and compliance are documented; specialist prescribing or consultation is documented; permitted and supported combination therapy requirements are met when applicable; and the patient has no FDA-labeled contraindication to the requested agent.12-month approval

    Patients without prior plan approval require initial evaluation review.

    Step-Therapy Requirements

    StepConditionRequired therapyTiming and exceptions
    1AsthmaContinue asthma control therapy with the requested IL-5 inhibitor. Therapy may include an inhaled corticosteroid (ICS), ICS/LABA, LTRA, LAMA, or theophylline.Use for at least 3 months with adherence for 90 days within the past 120 days where specified. An intolerance, hypersensitivity, or FDA-labeled contraindication to required controller therapy may satisfy an exception.
    1COPDContinue COPD inhaled maintenance therapy with the requested IL-5 inhibitor, including ICS/LAMA/LABA triple therapy or LAMA/LABA dual therapy.ICS therapy requires at least 3 months with adherence for 90 days within the past 120 days where applicable. An intolerance, hypersensitivity, or FDA-labeled contraindication to ICS may satisfy an exception; LAMA/LABA dual therapy remains required.
    StepConditionRequired therapyTiming and exceptions
    1Chronic rhinosinusitis with nasal polyps (CRSwNP)Try one intranasal corticosteroid, such as fluticasone nasal spray, mometasone nasal spray, or Sinuva, and continue standard nasal-polyp maintenance therapy with the requested agent.The intranasal corticosteroid trial must last at least 4 weeks and show inadequate response. Intolerance, hypersensitivity, or an FDA-labeled contraindication to all intranasal corticosteroids may satisfy an exception. Standard maintenance therapy, such as nasal saline irrigation or an intranasal corticosteroid, must continue with the requested agent.
    StepConditionRequired therapyTiming and exceptions
    1Hypereosinophilic syndrome (HES)Document an inadequate response to oral corticosteroid, hydroxyurea, interferon-alfa, or an immunosuppressive agent, or document corticosteroid dependence. Continue existing HES therapy with the requested agent.An intolerance, hypersensitivity, or FDA-labeled contraindication to the applicable prior therapies may satisfy an exception. Existing therapy may include oral corticosteroid, hydroxyurea, interferon-alfa, cyclosporine, or methotrexate.

    Quantity Limits

    Target product presentations
    FasenraBenralizumab subcutaneous solution prefilled syringe, 30 mg/mL
    Fasenra penBenralizumab subcutaneous solution auto-injector, 30 mg/mL
    NucalaMepolizumab injectable, auto-injector, and prefilled syringe presentations, including 100 mg and 100 mg/mL strengths and a 40 mg/0.4 mL prefilled syringe
    Target agent(s)
    Standard ruleThe requested quantity must not exceed the program quantity limit
    Exception pathway 1If no maximum FDA-labeled dose exists for the indication, higher-dose therapy must be clinically supported
    Exception pathway 2

    Site-of-Care and Administration

    Billing Rule

    Verify office-administered product billing

    For Boeing, some groups may cover healthcare professional administered versions of Nucala and Fasenra under a route-of-administration exception through the pharmacy benefit; other groups may exclude these versions from the pharmacy benefit.

    • Nucala GPI: 44604055002120.
    • Fasenra GPI: 4460402000E520.
    • Verify the member group’s pharmacy-benefit coverage before billing.
    Policy Summary
    PayerPrime Therapeutics
    PolicyIL-5 Inhibitors Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date11-01-2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Fasenra or Nucala with required clinical documentation and specialist involvement.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Actions and Submission RequirementsPolicy BackgroundClinical DefinitionsInitial AuthorizationContinuation and RenewalStep-Therapy RequirementsQuantity LimitsSite-of-Care and Administration
    Baseline FEV1 is less than 80% of predicted.
  1. Use of an asthma biologic immunomodulator within the past 12 months, excluding sample use.
  2. ANY of the following

    • ALL of the following

      • No asthma biologic immunomodulator is currently used, and the patient has used a maximally tolerated inhaled corticosteroid for at least 3 months with adherence for 90 days within the past 120 days; chart notes are required.
      • The patient has an intolerance or hypersensitivity to one inhaled corticosteroid, or an FDA-labeled contraindication to all inhaled corticosteroids.
    • ANY of the following

      • The patient has used a LABA, LAMA, LTRA, or theophylline for at least 3 months with adherence for 90 days within the past 120 days; chart notes are required.
      • The patient has an intolerance or hypersensitivity to one LABA, LAMA, LTRA, or theophylline.
      • The patient has an FDA-labeled contraindication to all LABAs and all LAMAs.
  3. The patient will continue asthma control therapy in combination with the requested agent.
  4. ANY of the following

    • The patient is adherent to ICS for at least 3 months and 90 days within the past 120 days; chart notes are required.
    • The patient has an intolerance or hypersensitivity to one ICS.
    • The patient has an FDA-labeled contraindication to all ICSs.
  5. The patient is treated with LAMA/LABA dual therapy for at least 3 months and has been adherent for 90 days within the past 120 days; chart notes are required.
  6. The patient will continue COPD inhaled maintenance therapy in combination with the requested agent.
  7. At least 2 HES flares occurred within the past 12 months.
  8. Active signs or symptoms of an HES flare are present.
  9. ANY of the following

    • Inadequate response to oral corticosteroid, hydroxyurea, interferon-alfa, or an immunosuppressive agent.
    • Corticosteroid-dependent HES.
    • Intolerance or hypersensitivity to one accepted HES therapy.
    • FDA-labeled contraindication to hydroxyurea, interferon-alfa, all oral corticosteroids, and applicable immunosuppressive agents.
  10. Existing HES therapy will continue in combination with the requested agent.
  11. Symptoms have been present for at least 12 consecutive weeks.>= 12 consecutive weeks
  12. ANY of the following

    • Diagnosis confirmed by anterior rhinoscopy.
    • Diagnosis confirmed by nasal endoscopy.
    • Diagnosis confirmed by CT of the sinuses.
  13. ANY of the following

    • Inadequate response to one intranasal corticosteroid after at least 4 weeks.
    • Intolerance or hypersensitivity to one intranasal corticosteroid.
    • FDA-labeled contraindication to all intranasal corticosteroids.
  14. The patient will continue standard nasal polyp maintenance therapy in combination with the requested agent.
  15. Supports severe eosinophilic asthma while the patient is receiving high-dose inhaled corticosteroid or daily oral corticosteroid therapy
    Severe asthma baseline FEV1
    ThresholdBaseline FEV1 < 80% of predicted
    TimingMeasured prior to therapy with the requested agent
    Clinical contextQualifies as objective impairment supporting severe eosinophilic asthma
    COPD spirometry
    TestPost-bronchodilator spirometry
    ThresholdFEV1/FVC ratio < 0.7
    PurposeConfirms the COPD diagnosis for the requested agent
    COPD eosinophilic phenotype
    Phenotype thresholdBaseline blood eosinophils >= 300 cells/microliter
    TimingMeasured prior to therapy with the requested agent
    Clinical contextDefines the eosinophilic phenotype for COPD
    EGPA eosinophil count
    ThresholdBaseline blood eosinophils >= 1000 cells/microliter
    TimingMeasured prior to therapy for the requested indication
    Clinical contextProvides laboratory evidence for EGPA
    EGPA eosinophil percentage
    ThresholdBaseline eosinophils >= 10% on the white blood cell differential
    TimingMeasured prior to therapy for the requested indication
    Clinical contextAlternative laboratory evidence for EGPA when the absolute eosinophil threshold is not used
    HES duration and eosinophils
    Diagnosis durationFor Nucala, HES must have been diagnosed for at least 6 months
    Eosinophil thresholdBaseline blood eosinophils >= 1000 cells/microliter
    TimingBaseline value is measured prior to therapy with the requested agent
    CRSwNP symptom duration
    Minimum durationSymptoms consistent with chronic rhinosinusitis must persist for >= 12 consecutive weeks
    Required symptomsAt least two symptoms, such as nasal discharge, nasal obstruction or congestion, reduced sense of smell, or facial pressure or pain
    Diagnosis confirmationConfirmation may be by anterior rhinoscopy, nasal endoscopy, or CT of the sinuses
    Intranasal corticosteroid trial
    Trial durationAt least 4 weeks of intranasal corticosteroid therapy
    Response requirementThe patient must have tried and had an inadequate response to one intranasal corticosteroid
    Alternative pathwaysIntolerance, hypersensitivity, or an FDA-labeled contraindication to all intranasal corticosteroids may satisfy the requirement
    Maintenance therapy duration and adherence
    Therapy durationAt least 3 months of applicable maintenance therapy
    Adherence windowAdherence for 90 days within the past 120 days
    Asthma maintenanceMay include inhaled corticosteroid, LABA, LAMA, LTRA, or theophylline therapy
    COPD maintenanceRequires applicable ICS and LAMA/LABA dual or triple inhaled maintenance therapy
    Documentation Required

    Specialist and Concomitant-Therapy Requirements

    The prescriber must specialize in the patient’s diagnosis or document consultation with an appropriate specialist. The requested agent must also be used safely with concomitant immunomodulatory therapy.

    • Relevant specialists may include an allergist, immunologist, pulmonologist, otolaryngologist, or rheumatologist, depending on the indication.
    • The requested agent must not be combined with another immunomodulator unless the prescribing information does not limit the combination and supporting evidence is submitted.
    Documentation Required

    Clinical Records and Laboratory Results

    Submit chart notes and laboratory results that establish the diagnosis, disease phenotype, treatment response or severity, and applicable baseline measurements.

    • Depending on indication, documentation may include blood eosinophil count, FeNO, FEV1, post-bronchodilator FEV1/FVC ratio, eosinophil percentage, exacerbation history, and oral corticosteroid use.
    • For EGPA, submit required eosinophil results, asthma history, oral corticosteroid treatment details, and documentation that severe organ- or life-threatening manifestations are absent.
    Documentation Required

    Diagnosis, Treatment History, and Specialist Documentation

    Provide documentation supporting the requested diagnosis, prior treatment, treatment adherence, and indication-specific clinical need. The request must also identify the appropriate specialist or specialist consultation.

    • For severe eosinophilic asthma, document maximally tolerated inhaled corticosteroid use or applicable intolerance/contraindication, adherence, and continued asthma-control therapy.
    • For COPD, document maintenance therapy, adherence, exacerbation history, and continued ICS/LAMA/LABA or LAMA/LABA therapy.
    • For CRSwNP, document symptoms for at least 12 consecutive weeks, diagnostic confirmation by rhinoscopy, endoscopy, or CT, prior intranasal corticosteroid use or applicable intolerance/contraindication, and continued nasal-polyp maintenance therapy.
    • For other FDA-labeled or compendia-supported indications, document the diagnosis, age or indication support, and route of administration.
    Documentation Required

    Combination-Therapy Evidence

    When combination therapy with another immunomodulator is requested, submit evidence supporting the combination, such as clinical trials, phase III studies, or applicable treatment guidelines.

    • The prescribing information for the requested agent must not limit use with the other immunomodulator.
    • Compendia support may include AHFS, DrugDex level 1, 2a, or 2b evidence, or NCCN level 1, 2a, or 2b recommended use.
    Documentation Required

    Combination With Another Immunomodulator

    Document the clinical rationale for combining the requested agent with another immunomodulator. The combination must be permitted by the requested agent’s prescribing information and supported by submitted evidence.

    • Submit clinical trials, phase III studies, or guidelines supporting the specific combination.
    • Examples of other immunomodulators include TNF inhibitors, JAK inhibitors, and IL-4 inhibitors.
    Documentation Required

    Quantity-Limit Exception Documentation

    A quantity above the program limit requires documentation supporting the higher quantity and the applicable exception pathway.

    • If no maximum FDA-labeled dose exists for the indication, submit support for therapy with the higher dose.
    • If a maximum FDA-labeled dose exists, document that the requested quantity does not exceed it and explain why the dose cannot be achieved using a lower quantity of a higher strength within the program limit.

    Unsupported block type: denial_risk

    Denial Risk

    Renewal Requirements Not Met

    Renewal may be denied unless the patient was previously approved through the plan’s prior authorization process and has demonstrated clinical benefit with the requested agent.

    • For asthma, document current treatment and compliance with asthma-control therapy within the past 90 days.
    • For COPD, document current treatment and compliance with COPD inhaled maintenance therapy within the past 90 days.
    • For CRSwNP, document continuation of standard nasal-polyp maintenance therapy in combination with the requested agent.
    • Renewal also requires applicable specialist involvement, permitted concomitant therapy, supporting combination evidence when needed, and no FDA-labeled contraindication.
    Denial Risk

    Unsupported Combination Immunomodulator Therapy

    Combination immunomodulator therapy is not supported when the requested agent’s prescribing information limits the combination or when the required clinical evidence is absent.

    • Submit clinical trials, phase III studies, or guidelines supporting the combination when another immunomodulator will be used.
    • Without the prescribing-information allowance and supporting evidence, the request may be denied.
    Denial Risk

    FDA-Labeled Contraindication

    The requested agent must not be used when an FDA-labeled contraindication applies. Document review of contraindications for the requested agent.

    • The absence of an FDA-labeled contraindication is required for both initial and renewal approval.
    • A request may be denied when a labeled contraindication is present.
    Denial Risk

    Quantity-Limit Override Not Supported

    A higher-dose quantity exception is not supported unless the requested quantity satisfies the applicable FDA-label and clinical-support requirements.

    • If there is no maximum FDA-labeled dose, support for the higher dose is required.
    • If a maximum FDA-labeled dose applies, the requested quantity must not exceed it and the lower-quantity/higher-strength alternative must not achieve the required dose within the program limit.
    Denial Risk

    Clinical and Concomitant-Therapy Failures

    The request may be denied when specialist involvement, required concomitant maintenance therapy, or permitted immunomodulator use is not established.

    • The prescriber must be an appropriate specialist or document specialist consultation.
    • Patients must continue applicable asthma, COPD, or CRSwNP maintenance therapy unless an allowed intolerance or contraindication pathway applies.
    • Combination with another immunomodulator requires prescribing-information allowance and supporting evidence.
    Denial Risk

    Quantity Limit Exceeded Without Support

    A quantity above the program limit may be denied when the request does not include support for the higher quantity or does not meet the applicable FDA-labeled dose requirements.

    • Submit documentation explaining why the requested dose is medically necessary.
    • The request must either be supported when no maximum FDA-labeled dose exists or remain within the maximum FDA-labeled dose while demonstrating that a lower quantity of a higher strength cannot achieve the dose within the program limit.
    Disease-control support
    Inadequate control despite inhaled maintenance therapy, qualifying exacerbations, or recent COPD biologic immunomodulator use is required
    EGPA
    DefinitionEosinophilic granulomatosis with polyangiitis with qualifying eosinophilic laboratory evidence
    Required clinical historyHistory or presence of asthma
    Treatment pathwayQualifying oral corticosteroid treatment, intolerance or hypersensitivity, or an FDA-labeled contraindication pathway is required
    ExclusionSevere disease with organ- or life-threatening manifestations is not covered
    HES
    DefinitionHypereosinophilic syndrome with marked eosinophilia and evaluation for hypereosinophilia-related organ involvement
    Duration and laboratory evidenceFor Nucala, diagnosis must be at least 6 months and baseline eosinophils must be >= 1000 cells/microliter
    Disease activityAt least two HES flares within the past 12 months or active signs or symptoms of a flare
    ExclusionsNo identifiable non-hematologic secondary cause and no FIP1L1-PDGFRA-positive disease
  16. Combination therapy requirement: The patient will not use the requested agent with another immunomodulatory agent OR the prescribing information permits the combination and supporting clinical trials, phase III studies, or guidelines are submitted.
  17. If the quantity is within the maximum FDA-labeled dose, documentation must explain why the dose cannot be achieved with a lower quantity of a higher-strength product within the program limit